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Abstract: Anatomists of the 17th century described the milky
‘vasa lymphatica’ as the fourth kind of vessel, the ﬁrst three kinds
being arteries, veins andnerveswhichwere, at the time, considered
as such. The subsequent centuries demonstrated a role for these in
transport of interstitial ﬂuid and cells, aswell as a conduit for larger
molecules and tumour metastasis. Long recognised as a barrier
or as a conduit for infectious pathogens travelling within leuko-
cytes, research has focussed on the interaction of the lymphatic
system with intracellular microbes; from plague and tuberculosis,
to viruses and parasites. The potential for extracellular bacteria to
access this systemhas been largely ignored, as an accidental conse-
quenceofnormal interstitial ﬂuid transport.GroupAstreptococcus,
a virulent humanpathogen that is known for its capacity to dissem-
inate systemically, can rapidly access the lymphatic system and
local lymph nodes via a hitherto unrecognised but speciﬁc interac-
tionbetween its hyaluronan capsule, and the lymphatic endothelial
receptor LYVE-1. The consequences of this for infection pathogene-
sis and immunity, are emergingareasof research that are important
not only for streptococci, but for other major bacterial pathogens.
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Abstract: Global community his committed to achieving mea-
surable Global Development Goals (MDG). MDG 4 is speciﬁcally
dealing with reducing child mortality. Pneumonia and Diarrhea
are perhaps two very important contributing causes of child mor-
tality globally. While many developed countries have managed to
achieve theMD4 targets, most of devolving countries far behind in
achieving this important goal. Measuring pneumonia burden is dif-
ﬁcult since there iswide variation in its presentation particularly in
childrenand themultiple etiological agents associatedwith thedis-
ease. It is alsowell known that clinical signs ofmalaria andmeasles
overlap with those of pneumonia and there is lack of clinical signs
in mal nourished children leading to misclassiﬁcation error. How-
ever, a number of well conducted studies1,2,3,4,5 recently have
made it possible to arrive at reasonable estimates of pneumonia
burden particularly for preventable disease at both global levels
and regional levels. Black et al1 through a systematic analysis of
data onmortality as the startingpoint estimated that there is nearly
8.795million under 5mortality globally. Of thismore than 726mil-
lion (52%) occurred in the Sub—Saharan region and in the Indian
subcontinent contributed mainly by 5 countries, India, Nigeria, DR.
Congo, Pakistan and Afghanistan. Global Pneumonia mortality was
estimated to be 1.575 million globally. The Indian component of
this global mortality was estimated to be 0.371million (∼23%). The
Child Health Epidemiology Reference Group (CHERG) 2 established
by WHO arrived at estimates not much different from the earlier
results in 2012. They estimated the global burden of pneumonia
death in under 5 to be 1.396 million. In this study India contributed
to 43 million pneumonia episodes leading to 0.397 million under 5
deaths.
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